← Back to Home

Tracking Fibrosis Beyond Lung Function: Qureight Imaging AI Included in Phase 2 Pulmonary Fibrosis Trial

PROPEL-IPF will use CT imaging to quantify lung fibrosis alongside lung function assessments to evaluate the drug candidate PIPE-791. This approach may add structural evidence to the assessment of efficacy, but whether imaging changes can reliably reflect treatment benefits remains to be validated in the trial.

By SURL BioNews

In treating pulmonary fibrosis, changes in lung function and the progression of fibrosis within the lungs are related questions that require different tools to answer. Contineum Therapeutics will examine both aspects in a Phase 2 drug trial: in addition to measuring patients’ respiratory function, it will use artificial intelligence to analyze computed tomography images and track changes in lung structure.

Qureight announced on November 9 that its imaging biomarker Fibr8 had been selected as a secondary endpoint in the PROPEL-IPF trial. Both the company’s website and the announcement distributed through Business Wire confirm that this global study uses a randomized, double-blind, placebo-controlled design and is expected to enroll approximately 324 patients with idiopathic pulmonary fibrosis (IPF) to evaluate the efficacy, safety, and tolerability of once-daily oral PIPE-791 over 26 weeks. PIPE-791 targets lysophosphatidic acid receptor 1 (LPAR1, also known as LPA1).

The trial’s primary endpoint remains forced vital capacity (FVC), the total volume of air a participant forcibly exhales after taking a full breath. Fibr8 analyzes the extent of fibrosis visible on high-resolution computed tomography (HRCT), providing quantitative data on the burden of structural disease in the lungs. Using both measurements gives researchers an opportunity to compare whether changes in fibrosis on imaging correspond to changes in lung function during treatment.

This is also the most concrete research purpose of using AI in this trial. It converts images into trackable quantitative measures to help researchers understand the drug candidate’s effects on lung disease. However, inclusion as a secondary endpoint does not itself mean that Fibr8 has been proven to predict patient benefit, nor does it mean that PIPE-791 has demonstrated efficacy; the announcement concerns measurement arrangements within the trial, rather than treatment results.

The two announcements currently available for verification actually originate from the same company press release and cannot be regarded as two independent sources of validation. The announcement does not provide the size of Fibr8’s training dataset, its performance in independent validation, or imaging analysis results from this trial. Readers therefore cannot yet use this information to judge how consistently the model can identify subtle changes or how much clinical significance those changes have.

Qureight said it hopes this prospective study will build evidence on the relationship between structural changes in fibrosis and lung function to support future applications for formal regulatory qualification of the imaging biomarker. For antifibrotic drug development, another source of value from this trial will be testing how much information imaging quantification can add to existing lung function measures when assessing efficacy.

References

  1. Qureight
  2. Qureight via Business Wire, syndicated by Woonsocket Call